BRIEF-AbbVie announces positive pivotal phase 3 data for elagolix

* AbbVie announces positive pivotal phase 3 data demonstrating investigational medicine elagolix reduces menstrual and non-menstrual pelvic pain associated with endometriosis at the American Society for reproductive medicine scientific congress